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Transvascular lipoprotein transport in patients with chronic re-
nal disease.
Background. While increased plasma cholesterol is a well-
established cardiovascular risk factor in the general population,
this is not so among patients with chronic renal disease. We hy-
pothesized that the transvascular lipoprotein transport, in ad-
dition to the lipoprotein concentration in plasma, determines
the degree of atherosclerosis among patients with chronic renal
disease.
Methods. We used an in vivo method for measurement of
transvascular transport of low-density lipoprotein (LDL) in 21
patients with chronic renal disease and in 42 healthy control
patients. Autologous 131-iodinated LDL was reinjected intra-
venously, and the 1-hour fractional escape rate was taken as
index of transvascular transport.
Results. Transvascular LDL transport tended to be lower
in patients with chronic renal disease than in healthy control
patients [3.3 (95% CI 2.4–4.2) vs. 4.2 (3.7–4.2)%/hour; NS].
However, this tendency disappeared when transvascular LDL
transport was corrected for distribution volume of LDL [1.7
(1.2–2.2) vs. 1.8 (1.6–2.0) %/(hour × (L/m2)); NS]. There was
significant variation in transvascular LDL transport between di-
abetic patients with chronic renal disease, nondiabetic patients
with chronic renal disease, and healthy control patients [5.0
(3.2–7.8) vs. 3.0 (2.2–3.8) vs. 4.2 (3.6–4.8) %/hour; P < 0.01 after
adjustment for distribution volume of LDL]. This variation was
unlikely caused by altered hepatic LDL receptor expression or
glycosylation of LDL in diabetes patients.
Conclusion. Transvascular LDL transport may be increased
in diabetic patients with chronic renal disease, suggesting that
lipoprotein flux into the arterial wall is increased. A simi-
lar mechanism does not operate in nondiabetic patients with
chronic renal disease.
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Patients with chronic renal failure are at high risk for
developing atherosclerotic cardiovascular disease [1, 2].
Cardiovascular disease often occurs at an early stage in
the course (i.e., before end-stage renal failure is reached)
[3–5]. While increased plasma cholesterol concentration
is a well-established cardiovascular risk factor in the gen-
eral population [6], this is not the case among patients
with chronic renal failure [7, 8].
We therefore proposed the hypothesis that the
transvascular transport of lipoproteins from blood to the
vessel wall, rather than the lipoprotein concentration in
plasma, determines the degree of atherosclerosis among
patients with chronic renal failure. According to this, the
atherogenic effect of lipoproteins may be augmented if
the transvascular transport is high, and vice versa if the
transvascular transport is low.
In order to support this we developed a method to mea-
sure human fractional escape of low-density lipoprotein
(FERLDL) from the intravascular space using intravenous
injection of radioactively labeled autologous LDL [9]. By
this method we investigated patients with chronic renal
failure and compared them with healthy control patients
of similar age and sex distributions. We also measured
LDL size and distribution volumes of LDL, as this could
affect FER values.
METHODS
Subjects
We studied 21 patients (14 men and 7 women; age range
27–67 years) with chronic renal disease due to glomeru-
lonephritis (N = 4), polycystic renal disease (N = 4), ar-
terial hypertension (N = 3), diabetes mellitus (N = 3), or
other causes (N = 7). They used angiotensin-converting
enzyme inhibitors (N = 4), angiotensin II receptor an-
tagonists (N = 3), beta adrenoceptor blockers (N = 9),
calcium channel blockers (N = 8), diuretics (N = 10),
nitrates (N = 1), statins (N = 3), erythropoietins (N =
10), acetylsalicylic acids (N = 7), warfarin (N = 1), and
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insulin (N = 2). Ten were on continuous ambulatory peri-
toneal dialysis, 3 were anuric, and 1 had a history of acute
coronary occlusion. As control patients we studied 42
clinically healthy individuals with similar age and sex dis-
tributions as the patients (32 men and 10 women; age
range 23–73 years) who were free from any medication.
The healthy individuals were recruited from the Copen-
hagen City Heart Study, a major epidemiologic popula-
tion study of cardiovascular disease and risk factors [10,
11]. All participants gave written informed consent. The
study was in accordance with the Declaration of Helsinki
and was approved by the Copenhagen and Frederiksberg
Ethics Committee (file no. 01–302/97). The study was sur-
veyed by the Danish National Department of Isotope
Pharmacy, which permitted investigation of maximally
two subjects per week.
Procedures
Fractional escape rate of low density lipoprotein
(FERLDL) and albumin (FERalb) were measured by
means of plasma decay curves during 1 hour after intra-
venous injection of autologous 131-iodinated LDL (131I-
LDL) and commercially available 125-iodinated human
serum albumin (125I-albumin), respectively.
LDL was isolated from 100 mL of blood by sequen-
tial ultracentrifugation at 50,000 rpm for 20 hours in a
Beckman 50.4 Ti rotor (Beckman, Fullerton, CA, USA)
at 4◦C in solvent densities of 1.019 g/mL and 1.050 g/mL,
respectively, to exclude lipoprotein(a). 131-iodination of
LDL was done with 18.5 MBq 131-iodine using iodine
monochloride [12]. The iodination efficiency was 25 ±
5% (N = 54), which corresponds to 52 ± 13 cpm/
ng LDL protein. In the labeled preparations 98.6 ±
0.4% of the 131I radioactivity was precipitable with 15%
(vol/vol) trichloroacetic acid (TCA), and 5.6 ± 0.5% of
the 131I radioactivity was lipid-soluble [i.e., extractable
into chloroform-methanol (1:1, vol/vol)]. In fixed-density
ultracentrifugation analysis of labeled LDL in the pres-
ence of added carrier plasma, ≥96% of the total radioac-
tivity was in the LDL density range of 1.019 to 1.063 g/mL.
No evidence of fragmentation of the labeled LDL was
detected using a 3% to 8% Tris-Acetate Gradient Gel
followed by autoradiography. In all labeled preparations,
test for sterility was negative, and <5 pg of pyrogenes was
detectable per mL sample.
The participants met at 0800 hours after an 8-hour
fast and tobacco abstinence. A 17 G teflon cannula was
inserted in an antecubital vein in both arms, one for
blood sampling and one for injection. After 30 min-
utes’ rest at recumbency, the preparation containing 131I-
LDL (700 kBq) and 125I-albumin [500 kBq; code IFE-
IT.23S or IFE-IT.20S, Isopharma AS, Kjeller, Norway
(free 125I radioactivity <1.5 ± 0.2%)] was injected in-
travenously. Venous blood samples of 10 mL were drawn
without stasis in heparinized tubes before and at 10, 20,
30, 40, 50, and 60 minutes after injection. Proteins in
plasma (3 mL) and doses (0.1 mL with 2.9 mL unla-
beled plasma added) were precipitated at 4◦C with TCA
at a final concentration of 15% (vol/vol). Following mix-
ing and centrifugation, total radioactivity as well as ra-
dioactivity in the supernatant was counted for 20 minutes
in a double-channel gamma counter (1282 Com-
pugamma; LKB, Wallac, Turku, Finland). For both trac-
ers the TCA-precipitable radioactivity at each time point
was plotted versus time after logarithmic transformation.
FERLDL and FERalb (in %/h) were then calculated on
the basis of the slopes (b) of the best linear curves fit-
ted by the least squares method using the formula (1 −
60eb ) × 100%, thus assuming that radioactivities declined
monoexponentially with time (1-compartment system).
Distribution volumes of LDL (DVLDL) and albumin
(DValb = plasma volume) were calculated from the
amounts of injected radioactivities divided by the plasma
radioactivities at time zero, as derived from the intercepts
of the fitted lines for the two tracers, respectively. The ob-
tained DV values were corrected for body surface area
(m2) by the formula 0.007184 × weight0.425 × height0.725.
Curve fits of both 60 minutes and 30 minutes after rein-
jection were used.
The contribution of receptor-mediated elimination of
LDL from the intravascular compartment to FERLDL
during the 1-hour blood sampling period was elucidated
by comparing FERLDL with FERGly-LDL in 3 humans
without diabetes mellitus [9]. Glycosylated LDL is not
recognized by LDL receptors [13, 14], and thus the dif-
ference between FERLDL and FERGly-LDL represents re-
ceptor elimination. Glycosylation of LDL was performed
as previously described by others [13, 15, 16]. Autolo-
gous 131I-LDL (700 kBq) and autologous 125I-Gly-LDL
(500kBq) was reinjected under similar conditions as de-
scribed above. Venous blood samples of 10 mL were
drawn without stasis in heparinized tubes before and
at 10, 20, 30, 40, 50, and 60 minutes after reinjection.
Eleven additional blood samples were obtained during
the subsequent 6 days. Plasma was precipitated with
TCA and counted for radioactivity as described above.
For both tracers the logarithmically transformed TCA-
precipitable radioactivity was plotted versus time, and
FERLDL and FERGly-LDL were calculated as previously
described. Mean FERLDL was about 1%/h higher than
mean FERGly-LDL (3.6 ± 1.1 vs. 2.6 ± 1.1%/h). Moreover,
fractional catabolic rates, FCRLDL, and FCRGly-LDL (in
%/h), were calculated according to Matthews using the
formula (C1/b 1 + C2/b 2)−1, where b 1 and b 2 are slopes,
and C1 and C2 are intercepts of the late and initial linear
curve fits, respectively [17]. Mean FCRLDL was about 2
times higher than mean FCRGly-LDL (P < 0.01), docu-
menting that Gly-LDL was indeed glycosylated.
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The use of a 1-compartment system for calcula-
tion of FERLDL was validated by comparing FERLDL
with transvascular LDL permeability as described by
Matthews [17], which takes into account an extravascu-
lar protein compartment, receptor-mediated metabolism,
and excretion. In 8 subjects without diabetes, blood
samples were collected every tenth minute during the
first hour and subsequently once a day during the
next week upon reinjection of autologous 131I-LDL.
Transvascular LDL permeability using the multicompart-
ment model was calculated by the formula C1C2(b2 −
b1)2/(C1b2 + C2b1) [16]. There was a positive corre-
lation between FERLDL using 1-compartment kinetics
and transvascular LDL permeability using multicom-
partment kinetics (R2 = 0.41; N = 8; one-sided P <
0.05) [9]. The equation for the linear correlation
was 1-compartment FERLDL = 0.43 × multicompart-
ment FERLDL + 2.8 (all in %/h). The overestimation
of FERLDL by 1-compartment kinetics was most pro-
nounced in the lower range. Finally, we correlated
FERLDL to FCRLDL in 27 subjects, where FCRLDL was
calculated by multicompartmental analysis using the
SAAM II software (SAAM Institute, Seattle, WA, USA)
[18]. Because there was no correlation between FERLDL
and FCRLDL (R < 0.01; P = 0.99), it is unlikely that
metabolism (i.e., receptor-mediated elimination of LDL)
contributes to FERLDL to any significant degree.
Plasma concentrations of total cholesterol, LDL
cholesterol, HDL cholesterol, triglycerides, and crea-
tinine, and blood concentration of glucose were all
measured by commercially available assays (Roche
Diagnostics, GmbH, Mannheim, Germany) using a
Hitachi analyzer. Plasma concentration of C-reactive
protein (CRP) was measured by a highly sensitive
nephelometric method (Behring Diagnostica, Marburg,
Germany). Plasma concentration of insulin was mea-
sured by a fluoroimmunoassay. Fraction of glycosylated
hemoglobin in blood, hemoglobinA1c, was measured by
high-performance liquid chromatography. LDL particle
size was measured by non-denaturing pore gradient gel
electrophoresis as previously described [9, 19]. All blood
samples were drawn after an 8-hour fast and tobacco
abstinence. Urine concentration of albumin was mea-
sured by a micro enzyme-linked immunosorbent assay
(ELISA) method [20], and urine concentration of cre-
atinine by a photometric method (Vitros Crea Slide,
Johnson & Johnson, Rochester, MN, USA). Systolic and
diastolic blood pressures were measured by auscultation
using a manometer and an appropriately sized cuff. Body
mass index (kg/m2) was calculated as weight/height2.
Statistical analysis
Comparisons between groups were performed by Stu-
dent t test, ANOVA, or chi-square test. Factors associated
Table 1. Characteristics of patients with chronic renal disease and
age- and sex-matched healthy control patients
Control Uremia
(N = 42) (N = 21)
Men % 76 (63–89) 66 (46–86)
Age years 52 (48–56) 51 (46–56)
Smokers % 33 (14–52) 52 (31–73)
Systolic blood pressure 119 (115–123) 144 (136–152)a
mm Hg
Diastolic blood pressure 75 (71–79) 82 (79–86)b
mm Hg
Body mass index 24.5 (23.6–25.5) 27.6 (25.3–30.0)b
kg/m2
Plasma total cholesterol 5.2 (5.0–5.4) 5.6 (5.0–6.2)
mmol/L
Plasma LDL cholesterol 3.4 (3.2–3.6) 3.4 (2.9–3.9)
mmol/L
Plasma HDL cholesterol 1.36 (1.22–1.50) 1.14 (1.00–1.28)d
mmol/L
Plasma triglycerides mmol/Le 0.8 (0.7–0.9) 1.5 (1.1–2.0)a
Plasma insulin pmol/Le 26 (21–30) 44 (34–58)b
Plasma C-reactive protein 0.6 (0.5–0.9) 4.2 (2.4–7.4)a
mg/Le
Plasma creatinine lmol/Le 88 (85–92) 468 (377–580)a
Urine albumin/creatinine 0.50 (0.38–0.66) 60 (33–111)a
mg/mmole
Blood hemoglobin A1c % 5.7 (5.6–5.8) 6.8 (6.4–7.2)a
95% confidence intervals are given in parentheses.
aP < 0.001; bP < 0.005; cP < 0.01; dP < 0.05; econtinuous variables are shown
by means or geometric means.
with FERLDL were analyzed by linear regression analy-
ses. Plasma triglycerides, creatinine, insulin, and CRP, and
urine albumin/creatinine ratio were all log-transformed
before the analyses because of non-normal distribution.
P values < 0.05 were significant. We used the statistical
software SPSS for Windows version 11.0 (Chicago, IL,
USA).
RESULTS
Characteristics of patients and control patients are
shown in Table 1. Besides higher plasma creatinine and
urine albumin/creatinine, patients with chronic renal dis-
ease had higher blood pressure, body mass index, plasma
high sensitive CRP, plasma triglycerides, plasma insulin,
and blood hemoglobin A1c, and lower plasma HDL
cholesterol (Table 1). Furthermore, the diameter of the
LDL particles was smaller in patients than controls [mean
95% CI: 23.9 (23.7–24.0) vs. 24.2 (24.1–24.3) nm; P <
0.001] (Table 2).
Patients with chronic renal disease had similar FERLDL
and FERalb as healthy control patients (Table 2). There
was a tendency toward lower values among the patients,
but after correction for variations in DVLDL and DValb,
respectively, which were lower among patients than con-
trol, this tendency was abolished (Table 2).
Plasma decay curves of 1 representative patient with
uremia and 1 representative control are shown in
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Table 2. Fractional escape rates (FER) and distribution volumes
(DV) of LDL and albumin, and LDL size in patients with chronic
renal disease and age- and sex-matched healthy control patients
calculated by both the initial 60 and 30 minutes after reinjection
Control Uremia
(N = 42) (N = 21)
FERLDL60 %/hour 4.2 (3.7–4.7) 3.3 (2.4–4.2)
DVLDL60 L/m2 2.39 (2.30–2.48) 2.12 (1.97–2.27)b
FERLDL60/DVLDL60 1.8 (1.6–2.0) 1.7 (1.2–2.2)
%/(hour × (L/m2))
FERalb60 %/hour 5.6 (5.0–6.2) 4.8 (3.9–5.8)
DValb60 L/m2 2.36 (2.27–2.45) 2.08 (1.94–2.23)b
FERalb60/DValb60 2.4 (2.1–2.7) 2.5 (1.9–3.0)
%/(hour × (L/m2))
FERLDL30 %/hour 6.1 (5.0–7.2) 5.7 (4.3–7.1)
DVLDL30 L/m2 2.39 (2.30–2.48) 2.11 (1.92–2.30)b
FERLDL30 /DVLDL30 2.7 (2.2–3.2) 2.9 (2.0–3.8)
%/(hour × (L/m2))
FERalb30 %/hour 6.6 (5.5–7.7) 6.8 (5.1–8.5)
DValb30 L/m2 2.35 (2.26–2.44) 2.05 (1.89–2.21)b
FERalb30/DValb30 2.9 (2.4–3.4) 3.4 (2.5–4.3)
%/(hour × (L/m2))
LDL diameter nm 24.2 (24.1–24.3) 23.9 (23.7–24.0)a
Data are means with 95% confidence intervals.
aP < 0.001; bP < 0.005.
Albumin
3.2
3.5 LDL
Control
2.9
3.2
Urem
ia
0 20 40 600 20 40 60
5.8
6.4
4.9
5.5
Pl
as
m
a 
ra
di
oa
ct
ivi
ty,
 
×
10
3  
cp
m
/m
L
Minutes after reinjection
Fig. 1. Plasma decay curves of 1 representative patient with chronic
renal disease and 1 representative control.
Figure 1. Because there could be an inflection point at
about 30 minutes, FER and DV were also calculated
only using the initial 30 minutes after reinjection. By this
method there was no difference in FERLDL or FERalb
between patients with chronic renal disease or controls
(Table 2).
There was significant variation in FERLDL between di-
abetic patients with chronic renal disease, nondiabetic
patients with chronic renal disease, and healthy control
patients [mean 95% CI: 5.0 (3.2–7.8) vs. 3.0 (2.2–3.8)
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Fig. 2. FERLDL in diabetic patients with chronic renal disease (uremia
+ DM), nondiabetic patients with chronic renal disease (uremia −
DM), and healthy control patients, calculated by 60-minute curve fits.
Mean with SE are shown. P < 0.05 by ANOVA.
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Fig. 3. DVLDL diabetic patients with chronic renal disease (uremia +
DM), nondiabetic patients with chronic renal disease (uremia − DM),
and healthy control patients, calculated by 60-minute curve fits. Mean
with SE are shown. P = 0.005 by ANOVA.
vs. 4.2 (3.6–4.8) %/h; P < 0.05] (Fig. 2). The difference
in FERLDL between nondiabetic patients and control
patients could partly be explained by the variations in
DVLDL, whereas the difference in FERLDL between di-
abetic patients and nondiabetic patients may have been
underestimated due to variations in DVLDL (Fig. 3). Thus,
inclusion of DVLDL as a covariate in the ANOVA model
strengthened the significance of the variation in FERLDL
between the three groups (P < 0.01).
Neither FERLDL nor FERalb was significantly corre-
lated to any of the variables listed in Table 1 or to DValb,
DVLDL, or LDL size. There was a tight positive correla-
tion between FERLDL and FERalb (R2 = 0.74; P < 0.001).
DISCUSSION
In the present study we measured the fractional escape
of LDL from the intravascular compartment, FERLDL, by
a noninvasive in vivo isotope technique in a group of pa-
tients with chronic renal disease and a group of age- and
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sex-matched healthy control patients. Renal patients
tended to have lower FERLDL than healthy control pa-
tients, but this was probably due to a smaller intravascular
compartment. Thus, correction for differences in distri-
bution volumes of LDL abolished this difference. It is
therefore unlikely that uremia, per se, leads to elevated
transvascular transport and intimal deposition of LDL.
Thus, the high incidence of atherosclerotic cardiovascular
disease among patients with chronic renal disease [1–5]
may be explained by other mechanisms (e.g., by elevated
levels of triglyceride-rich lipoproteins and reduced levels
of HDL in plasma), as also observed in the present study.
Previously we observed that individuals with diabetes
mellitus have increased FERLDL compared with nondi-
abetic healthy individuals [9, 21]. When patients with
chronic renal disease due to diabetic nephropathy were
compared with patients with chronic renal disease due to
other causes, and with healthy control patients, we found
higher FERLDL in patients with chronic renal disease due
to diabetes than in nondiabetic patients with chronic re-
nal disease. According to our previous observations [9,
21], this may be due to the diabetes state, per se, rather
than the diabetic nephropathy. However, because this ob-
servation was based on only three patients with diabetic
nephropathy, this could be a chance finding. It therefore
has to be validated in a larger sample of diabetes patients
with chronic renal disease.
Another obvious possibility apart from the above-
mentioned considerations is that FERLDL reflects
metabolism of LDL rather than transvascular transport.
However, there was no association between FERLDL and
FCRLDL as calculated by the SAAM II method [18]. This
would have been the case if FERLDL was influenced by
LDL metabolism.
Glycosylation of LDL could also influence the disap-
pearance of LDL from the intravascular compartment:
glycosylated LDL is not recognized by LDL recep-
tors [13, 14], as confirmed by the significantly lower
FCRGly-LDL than FCRLDL in our validation experi-
ments. We therefore studied the contribution of receptor
elimination to FERLDL by measuring FERGly-LDL and
FERLDL simultaneously. FERGly-LDL was about 1%/h
lower than FERLDL in nondiabetic humans, indicating
that receptor elimination contributes to FERLDL only by
approximately 1%/h (corresponding to about one third of
FERLDL). This is in accordance with the overestimation
of FERLDL by 1–3%/h when our 1-compartment model
is used compared with a multicompartment model that
subtracts the contribution of metabolism [17]. It is also
in accordance with the slightly bigger distribution volume
of LDL than albumin. Importantly, because glycosylation
of LDL particles may be increased in diabetes patients
due to the hyperglycemic milieu, LDL glycosylation does
not explain the difference in FERLDL between diabetic
patients with chronic renal disease and nondiabetic pa-
tients with chronic renal disease observed in this study,
but rather the difference may be underestimated.
Because FERLDL also was independent of LDL size,
systemic arterial blood pressure, and endothelial surface
area as reflected by the plasma volume, we suggest the el-
evated FERLDL in diabetes patients to result mainly from
increased transvascular permeability. This could be a con-
sequence of endothelial cell death or damage [22–24] due
to, for example, hyperinsulinemia [25–27], or to circu-
lating advanced glycation end products (AGE) inducing
transvascular hyperpermeability [28–31]. However, other
authors have observed increased intimal LDL accumula-
tion before the formation of AGE and suggest a direct
effect of hyperglycemia on the vessel wall [32]. Because
increased arterial LDL permeability is associated with
increased development of atherosclerosis after exposure
to hyperlipidemia [33], increased arterial leakiness may
explain accelerated atherogenesis in diabetes, but not in
patients with chronic renal disease.
The main proportion of transvascular LDL transport
probably takes place in the capillaries. However, there
exists indirect evidence for similar transport of albumin
and lipoproteins in capillaries and arteries [34]. Further-
more, the tight positive correlation between FERLDL and
FERalb observed in this study is analogous with the corre-
lation between the transport of LDL and albumin across
the arterial wall in rabbits [35]. The significantly lower
FERLDL than FERalb is in accordance with the three
times larger size of LDL particles than of albumin.
CONCLUSION
This human in vivo study has shown elevated fractional
escape of LDL particles from the intravascular compart-
ment among patients with diabetes mellitus and chronic
renal disease. We believe that this difference is not caused
by altered LDL receptor expression in the liver, glycosy-
lation of LDL, or small LDL size. Rather, this is likely due
to increased transvascular leakage of LDL in diabetes
patients, potentially leading to increased LDL accumula-
tion in the vessel wall, and thus, progressed atherosclero-
sis. This mechanism seems not to operate in nondiabetic
individuals with chronic renal disease.
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